Latest Perrigo Company Stories
PARSIPPANY, N.J., July 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-approved products and two undisclosed development-stage products. Commercialized products in the portfolio include: Ciclopirox shampoo 1% Ammonium...
In the news release, Perrigo Closes Acquisition of Paddock Labs, issued 26-Jul-2011 by Perrigo Company over PR Newswire, we are advised by the company that the fourth paragraph, second sentence, should read "The total revenues from marketed products represent less than 0.2% of the combined entities' total FY11 revenues" rather than "less than 2%" as originally issued inadvertently. The complete, corrected release follows: Perrigo Closes Acquisition of Paddock Labs ALLEGAN, Mich., July...
ALLEGAN, Mich., July 26, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products for approximately $540 million in cash. Perrigo Chairman and CEO Joseph C. Papa stated, "We are very pleased to welcome the Paddock team to the Perrigo family. This acquisition is another important...
ALLEGAN, Mich., July 21, 2011 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex gum USP, 2 mg and 4 mg cinnamon flavor. The product will be marketed under store brand labels and is comparable to GlaxoSmithKline's Nicorette® Cinnamon Surge(TM) coated gum, which is a stop smoking aid. "This approval of coated cinnamon nicotine gum...
ALLEGAN, Mich., June 29, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products. Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as possible. As we...
ALLEGAN, Mich., June 15, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories Inc.) has begun shipping Triamcinolone Acetonide Nasal Spray. Perrigo's partner Teva was the first applicant to file a complete ANDA with a Paragraph IV certification for Nasacort AQ and will be launching the product with 180 days of generic exclusivity. The Hatch Waxman litigation between Teva...
ALLEGAN, Mich., June 3, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Goldman Sachs 32nd Annual Global Health Care Conference on Thursday, June 9th, 2011 at 10:30 AM (PT) at the Terranea Resort in Rancho Palos Verdes, CA. Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas,...
ALLEGAN, Mich., May 18, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB's Xyzal® Oral Solution. Synthon believes it has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity....
ALLEGAN, Mich., May 16, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Ranitidine 150 (regular and cool mint), a generic version of Zantac 150®. We expect to launch early in our fiscal 2012. Zantac 150 (ranitidine) is indicated for the relief of heartburn associated with acid indigestion and sour stomach and prevents...
ALLEGAN, Mich., May 10, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by Nycomed US Inc. by taking a license under all relevant patents. Under the terms of the settlement, Perrigo can launch a generic version of Cutivate® lotion 0.05% on September 22, 2012, or earlier under certain circumstances. Cutivate® (fluticasone) lotion is indicated for the relief of the...
